Avicanna is Pleased to Announce the Initial Network of Brands on the MyMedi.ca Platform
July 28 2023 - 7:30AM
Avicanna Inc. (“
Avicanna” or the
“
Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a
biopharmaceutical company focused on the development, manufacturing
and commercialisation of plant-derived cannabinoid-based products
is pleased to announce its initial portfolio offering and network
in anticipation of the MyMedi.ca platform’s launch in early August.
In line with the Company’s commitment to provide
continuity of care to Canadian patients serviced by Medical
Cannabis by Shoppers and to make available a new cannabis care
platform that will offer patients a broad and diverse portfolio of
products, the Company is pleased to announce the initial network of
brands available on MyMedi.ca.
“We are pleased by the level of commitment
towards patients that we have seen and the concrete support of this
distinct group of Canadian licensed producers that have worked
towards the timely launch of the new cannabis care platform,
MyMedi.ca. We look forward to continuing to work collaboratively
towards the goals of establishing MyMedi.ca as a leading cannabis
care platform and towards taking steps to enhance the patient
journey,” stated Aras Azadian, CEO of Avicanna.
The featured brands that will be available for
purchase on MyMedi.ca include the list below, with more to
come.
CB4 |
Organigram |
Bhang |
Peace Naturals |
Big Bag O’ Buds |
Pure Sunfarms |
Canna Farms |
Pura Earth |
Countryside |
re+PLAY |
Edison |
RHO Phyto |
Ellevia |
Sanna |
Spinach FEELZ |
Shatterizer |
Highly Dutch |
Shred |
Indiva |
Shred’ems |
Kaiser Day |
SOURZ by Spinach |
Medipharm Labs |
Spinach |
Medisenol |
The Green Organic Dutchman |
Monjour |
True North |
Northbound |
Viola |
Ollive |
Wana |
Olli |
White Rabbit |
About Avicanna Inc.
Avicanna is a commercial-stage international
biopharmaceutical company focused on the advancement and
commercialization of evidence-based cannabinoid-based products for
the global medical and pharmaceutical market segments. Avicanna has
an established scientific platform including R&D and clinical
development that has led to the commercialization of more than
thirty products across various market segments:
- Medical Cannabis &
Wellness Products (RHO
Phyto™): The formulary offers a
diverse range of proprietary formulations including oral,
sublingual, topical, and transdermal deliveries with varying ratios
of cannabinoids and is supported with ongoing patient, and medical
community education. RHO Phyto has been established as a leading
medical brand in Canada and is currently available nationwide to
patients across several medical channels and continues to expand
into new international markets.
- Pharmaceutical Preparations
and Pipeline: Leveraging Avicanna’s
scientific platform, vertical integration, and real-world evidence,
Avicanna has developed an extensive pipeline of patent-pending drug
candidates that are indication-specific and in various stages of
clinical development and commercialization. These cannabinoid-based
drug candidates look to address unmet medical needs in the areas of
dermatology, chronic pain, and various neurological disorders.
Avicanna’s first pharmaceutical preparation (Trunerox™) is in the
drug registration stage in South America.
- MyMedi.ca
Medical Cannabis Care Portal:
MyMedi.ca is Avicanna’s medical cannabis care platform that is
formed with the aim to better serve medical cannabis patients’
needs and enhance the patient journey. MyMedi.ca is expected to
launch during August 2023 and will feature diverse and
scientifically curated products from leading Canadian licensed
producers in addition to pharmacist led patient support programs
and educational resources to facilitate the incorporation of
medical cannabis into health care regimens. MyMedi.ca also provides
specialty services to distinct patient groups such as veterans and
collaborating with public and private providers for adjudication
and reimbursement.
Click to watch Avicanna’s Corporate Video 2022
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit our
website, contact Ivana Maric by email at info@avicanna.com or
follow us on social media
on LinkedIn, Twitter, Facebook, or Instagram.
The Company posts updates through videos from
the Company YouTube channel.
Cautionary Note Regarding Forward-Looking Information
and Statements
This news release contains “forward-looking
information” within the meaning of applicable securities laws.
Forward-looking information contained in this news release may be
identified using words such as, “may”, “would”, “could”, “will”,
“likely”, “expect”, “anticipate”, “believe, “intend”, “plan”,
“forecast”, “project”, “estimate”, “outlook” and other similar
expressions. Although the Company believes that the expectations
and assumptions on which such forward looking information is based
are reasonable, undue reliance should not be placed on the
forward-looking information because the Company can give no
assurance that they will prove to be correct. Actual results and
developments may differ materially from those contemplated by these
statements. Forward-looking information is subject to a variety of
risks and uncertainties that could cause actual events or results
to differ materially from those projected in the forward-looking
information. Such risks and uncertainties include but are not
limited to current and future market conditions, including the
market price of the common shares of the Company, and the risk
factors set out in the Company’s annual information form dated
March 31, 2023 filed with the Canadian securities regulators and
available under the Company’s profile on SEDAR at www.sedar.com.
The statements in this news release are made as of the date of this
release. The Company disclaims any intent or obligation to update
any forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
Avicanna (TSX:AVCN)
Historical Stock Chart
From Apr 2024 to May 2024
Avicanna (TSX:AVCN)
Historical Stock Chart
From May 2023 to May 2024